Landmark Bio Joins Artis BioSolutions to Strengthen Advanced Therapy Manufacturing

• Landmark Bio has been acquired by Artis BioSolutions, a newly launched company focused on genetic medicine development and manufacturing.

• The acquisition will enable Landmark Bio to scale its operations and enhance its capabilities in advanced therapy manufacturing.

Landmark Bio has been acquired by Artis BioSolutions (“Artis”), a newly launched company focused on streamlining the discovery, process development, and manufacturing of genetic medicines. The acquisition will allow Landmark Bio to expand its capabilities and continue its mission of translating groundbreaking research into life-changing therapies.

Founded in 2021, Landmark Bio was established by leaders from academia, industry, and Boston’s top research hospitals to address bottlenecks in advanced therapy development. It provides services spanning preclinical development through commercialization, including GMP manufacturing, analytical and formulation development, QC testing, and CMC consulting. By joining Artis, Landmark Bio aims to scale its operations and enhance access to high-quality development and manufacturing capabilities across the advanced therapy sector.

“Landmark Bio was born from a bold vision shared by our founding partners – to remove barriers in the manufacturing of advanced therapies and accelerate the development of life-changing medicines,” said Ran Zheng, CEO of Landmark Bio. “Joining Artis BioSolutions marks an exciting new chapter for Landmark Bio. Together, we will stay true to our mission as we scale our operations to bring breakthrough therapies to more patients.”

Artis BioSolutions, backed by initial funding from Oak HC/FT, sees the acquisition as a step toward expanding access to cutting-edge development and manufacturing services. According to Brian Neel, CEO of Artis BioSolutions, the combination of Landmark Bio’s expertise and Artis’s strategic vision will help accelerate innovation and improve patient access to advanced therapies.

Landmark Bio will continue to operate as a distinct entity under Artis, maintaining its headquarters in Watertown, MA, along with its existing teams and state-of-the-art facilities.